Oracle Health Sciences InForm Advanced Molecular Analytics Enables Life Sciences Organizations to Incorporate Genomic Data Into Clinical R&D for Targeted, Biomarker-Driven Clinical Trials

Oracle Health Sciences InForm Advanced Molecular Analytics Enables Life Sciences Organizations to Incorporate Genomic Data Into Clinical R&D for Targeted, Biomarker-Driven Clinical Trials

Solution Extends the Capabilities of Oracle Health Sciences InForm GTM to Effectively Collect, Store and Analyze Genomic Data

BOSTON, MA, Mar 25, 2014 (Marketwired via COMTEX) -- ORACLE INDUSTRY CONNECT -- Oracle ORCL +0.84%

News Summary Biomarkers are becoming a key component of clinical trial design, enabling researchers to rapidly find subjects with similar clinical and omics characteristics. Oracle Health Sciences InForm Advanced Molecular Analytics is one of the first commercially available cloud-delivery solutions to incorporate genomics into the clinical data capture and management process. Integrated with Oracle Health Sciences InForm GTM, the solution enables clinical researchers to effectively capture, aggregate and analyze molecular data along with clinical data to provide the information needed to identify new predictive biomarkers. The solution facilitates the stratification of patients into target populations of responders to accelerate trials and improve drug and therapeutic outcomes.

News Facts

--  Oracle Health Sciences today announced Oracle Health Sciences InForm
            Advanced Molecular Analytics. Integrated with Oracle Health Sciences
            InForm GTM, the solution enables clinical trial managers to
            systematically and effectively collect, store and analyze genomic data
            captured in a clinical trial.
        --  The new capabilities of Oracle Health Sciences InForm Advanced
            Molecular Analytics help life sciences organizations to stratify
            patients and reduce research and development costs by leveraging
            targeted drug development approaches and decreasing study size and
            length. The solution also helps researchers identify new indications
            and therapies through post-trial, cross-study analysis with molecular
            data.
        --  Collecting biomarker data is typically a difficult manual effort,
            aggregating data scattered across spreadsheets, file systems and
            siloed transaction systems. With Oracle Health Sciences InForm
            Advanced Molecular Analytics, researchers have consolidated access to
            both clinical and genomic data for numerous purposes, such as
            submission or the design of more exploratory translational research
            studies, including those that can generate petabytes of data from
            thousands of whole genome sequences.
        --  Life sciences organizations can gain a single, integrated view of
            genomic, genetic and clinical data, enabling clinical researchers to
            identify and validate new targets. The solution supports multiple
            omics modalities and targeted gene panels and can scale to handle
            hundreds of thousands of whole genomes.
        --  Clinical researchers can study patient genomic profiles, analyze
            differences and compare molecular data against common large public
            domain data sets, such as The Cancer Genome Atlas -- streamlining
            analysis and increasing statistical power.
        --  The Oracle Health Sciences InForm Advanced Molecular Analytics
            solution leverages proven technology from Oracle Health Sciences
            Translational Research Center to deliver one of the first commercially
            available "molecular-aware" clinical data capture and management
            solutions.
        --  Oracle Health Sciences InForm Advanced Molecular Analytics is deployed
            as software-as-a-service (SaaS) and is fully integrated with the
            Oracle Health Sciences InForm Cloud Service. As a comprehensive and
            commercially available SaaS solution, life sciences organizations
            avoid the cost and time associated with building and maintaining
            custom solutions.

Supporting Quotes

        --  "As clinical trial design advances and becomes more targeted, new
            dynamics emerge in clinical research and development, such as the
            increasing need to quickly and reliably identify and validate
            biomarker hypotheses," said Mukhtar Ahmed, global vice president of
            product strategy, Oracle Health Sciences. "Oracle Health Sciences
            InForm Advanced Molecular Analytics expands the industry leading
            capabilities of Oracle Health Sciences InForm with new genomic
            management and analysis capabilities to facilitate more targeted trial
            design and drug development."
        --  "The adoption of our translational research platform in the healthcare
            sector by top-tier academic medical centers demonstrates that our
            genomics solutions have been tried, tested and shown to scale at an
            enterprise level," said Jonathan Sheldon, PhD, global vice president,
            Oracle Health Sciences. "With the release of Oracle Health Sciences
            InForm Advance Molecular Analytics, we are delivering a
            'biomarker-aware' clinical platform to help enable sponsors to design
            more targeted genomics studies."

 

Supporting Resources

--  Oracle in Health Sciences
        --  Oracle Health Sciences InForm
        --  Oracle Health Sciences Translational Research Center
        --  Oracle Health Sciences Cohort Explorer
        --  Oracle Health Sciences Omics Data Bank
        --  Follow Oracle Health Sciences on Twitter
        --  Join the Oracle Health Sciences Community on Facebook
        --  Oracle Health Sciences on YouTube
       

 

About Oracle Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle ORCL +0.84% , visit www.oracle.com .

About Oracle Health Sciences At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health. We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. For more information, visit http://www.oracle.com/us/industries/health-sciences/index.html .

About Oracle Industry Connect Oracle Industry Connect, taking place in Boston March 25-26, 2014, brings industry leaders together to share deep domain expertise, insights and industry-specific best practices. This leadership event features customer-led content including visionary keynotes, executive-level networking and in-depth case studies designed to help organizations meet industry-specific challenges. For more information, please visit www.oracleindustryconnect.com .

Trademarks Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Disclaimer The above is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle's products remains at the sole discretion of Oracle Corporation.


Contact Info

        Samantha Thai
        Oracle
        +1.510.917.5564
        Email Contact

        Mary Tobin
        O'Keeffe & Company
        +1.503.658.7396
        Email Contact
       

SOURCE: Oracle Corporation

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.